GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WPD Pharmaceuticals Inc (OTCPK:WPDPF) » Definitions » Net Issuance of Preferred Stock

WPD Pharmaceuticals (WPD Pharmaceuticals) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is WPD Pharmaceuticals Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

WPD Pharmaceuticals's net issuance of preferred for the three months ended in Sep. 2023 was $0.00 Mil. The number is 0, which means that WPD Pharmaceuticals has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

WPD Pharmaceuticals's net issuance of preferred for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

WPD Pharmaceuticals Net Issuance of Preferred Stock Historical Data

The historical data trend for WPD Pharmaceuticals's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WPD Pharmaceuticals Net Issuance of Preferred Stock Chart

WPD Pharmaceuticals Annual Data
Trend Jan11 Jan12 Jan13 Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Dec20
Net Issuance of Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

WPD Pharmaceuticals Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Mar22 Jun22 Sep22 Mar23 Jun23 Sep23
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

WPD Pharmaceuticals Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WPD Pharmaceuticals Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of WPD Pharmaceuticals's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

WPD Pharmaceuticals (WPD Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WPD Pharmaceuticals Inc (OTCPK:WPDPF) » Definitions » Net Issuance of Preferred Stock
Comparable Companies
RGMP ADXS CNBX AGTX HSTO QRON PTE ATRX VLON CYTR OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN ALNY
Traded in Other Exchanges
N/A
Address
750 West Pender Street, Suite 401, Vancouver, BC, CAN, V6C 2T7
Website
https://www.wpdpharmaceuticals.com
WPD Pharmaceuticals Inc is a biotechnology research and development company. It focuses on oncology, research, and development of medicinal products involving biological compounds and small molecules. The company has eight novel drug candidates which are in clinical development and pre-clinical development stage.